Parexel Introduces Expert Series—New Medicines, Novel Insights
Parexel has announced the launch of a new expert series, New Medicines, Novel Insights. The series will feature insights from the company’s global, cross-functional experts analyzing trends impacting drug development and offering evidence-based guidance to the biopharmaceutical industry.
The inaugural report—Advancing Rare Disease Drug Development—explores the unique regulatory, scientific, and market access challenges surrounding rare disease drug development and shares best practices to address them.
To view the full New Medicines, Novel Insights: Advancing Rare Disease Drug Development report and subscribe to receive future reports, visit the interactive experience.
Reference
Parexel Introduces Expert Series – New Medicines, Novel Insights. (2023, February 28). GlobeNewswire.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Rybrevant Plus Lazcluze Shows Over One-Year Survival Boost in EGFR-Mutated NSCLC Patients
January 7th 2025Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current standard of care, Tagrisso (osimertinib), for patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
